Juno Therapeutics, Inc. (NASDAQ:JUNO) closed its last session at $27.81 with the change of -31.87%. The market capitalization of the company is $2.81B with an average Volume of 1.41 million shares. The stock currently has its 52-Week High range of $57.82 and 52-week low range of $22.37. The Price to Book (P/B) ratio stands at 3.41. The stock traded total quantity of 18.95 million shares.
For the current Fiscal Quarter, 8 analysts have given an average earnings per share forecast of $-0.37. The Low Earnings per share estimate of the current Quarter is $-0.89 and High Estimate is set at $0.08 according to these Analysts opinions. The Previous Year EPS of this Quarter is $-0.35.
According to 9 analysts, an average sales Estimate of the current Fiscal quarter is $16.04M. The lower sales estimate is $3.80M and higher sales estimate is $50.00M according to these Analysts thoughts.
The Company currently has Highest Price Target of $80 and Lowest Price Target of $35. It has Median Price Targets of $48. Mean price target is set at $50.27 after consensus analysis of 11 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 0 analysts have assigned this stock as Strong Buy where 0 assigned Buy, 0 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.
Depomed, Inc. (NASDAQ:DEPO) ended its last trade at $18.77 with the move of +0.05%. The company has market value of $1.15B with the total traded volume of 1.54 million. The stock currently has its 52-Week top value of $33.74 and 52-week down value of $12.25. The price to book (P/B) ratio of the company is 3.82. Its previous closing price was recorded at $18.76.
For the current Fiscal Quarter, 12 analysts have given an Average earnings estimate of $0.26 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $0.12 while High Estimate is $0.32. The Previous Year EPS of this Quarter is $0.27.
According to 11 analysts, an Average Revenue Estimate of the current Fiscal quarter is $118.82M. According to them, the Low Revenue estimate is $115.57M and High Revenue estimate is $122.00M.
The Company currently has High Price Target of $28. The Low and Mean Price Targets are $20 and $23.73 respectively. These price targets are set after consensus analysis of 11 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month, 2 analysts have given this stock as Strong Buy where 9 issued Buy, 2 analysts think that it’s a Hold, 0 told Underperform and0 assigned Sell rating.